Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aaron L Boster

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Neurology. Clinical Practice|November 1, 2013
Multiple sclerosis: Five new thingsJacqueline A Nicholas, Aaron L Boster, Michael K Racke
Expert Review of Neurotherapeutics|May 1, 2015
Glatiramer acetate: long-term safety and efficacy in relapsing-remitting multiple sclerosisAaron L Boster, Corey C Ford, Orit Neudorfer, et al.
Neuromodulation : Journal of the International Neuromodulation Society|July 20, 2016
Best Practices for Intrathecal Baclofen Therapy: TroubleshootingMichael Saulino, David J Anderson, Jennifer Doble, et al.
Neuromodulation : Journal of the International Neuromodulation Society|July 20, 2016
Best Practices for Intrathecal Baclofen Therapy: Patient SelectionMichael Saulino, Cindy B Ivanhoe, John R McGuire, et al.
Pediatric Neurology|December 11, 2008
Pediatric-onset multiple sclerosis in African-American black and European-origin white patientsAaron L Boster, Christina F Endress, Stephanie A Hreha, et al.
Neuromodulation : Journal of the International Neuromodulation Society|July 20, 2016
Best Practices for Intrathecal Baclofen Therapy: Screening TestAaron L Boster, Susan E Bennett, Gerald S Bilsky, et al.
Neuromodulation : Journal of the International Neuromodulation Society|July 20, 2016
Best Practices for Intrathecal Baclofen Therapy: Dosing and Long-Term ManagementAaron L Boster, Roy L Adair, Judith L Gooch, et al.
JAMA Neurology|January 23, 2013
Lessons learned from fatal progressive multifocal leukoencephalopathy in a patient with multiple sclerosis treated with natalizumabAaron L Boster, Jacqueline A Nicholas, Ilir Topalli, et al.
Stem Cells Translational Medicine|January 17, 2015
Concise review: modeling multiple sclerosis with stem cell biological platforms: toward functional validation of cellular and molecular phenotypes in inflammation-induced neurodegenerationJoshua C Orack, Michela Deleidi, David Pitt, et al.
Therapeutic Advances in Neurological Disorders|May 26, 2021
Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trialAlasdair J Coles, Douglas L Arnold, Ann D Bass, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Neurology. Clinical Practice|November 1, 2013
Multiple sclerosis: Five new thingsJacqueline A Nicholas, Aaron L Boster, Michael K Racke
Expert Review of Neurotherapeutics|May 1, 2015
Glatiramer acetate: long-term safety and efficacy in relapsing-remitting multiple sclerosisAaron L Boster, Corey C Ford, Orit Neudorfer, et al.
Neuromodulation : Journal of the International Neuromodulation Society|July 20, 2016
Best Practices for Intrathecal Baclofen Therapy: TroubleshootingMichael Saulino, David J Anderson, Jennifer Doble, et al.
Neuromodulation : Journal of the International Neuromodulation Society|July 20, 2016
Best Practices for Intrathecal Baclofen Therapy: Patient SelectionMichael Saulino, Cindy B Ivanhoe, John R McGuire, et al.
Pediatric Neurology|December 11, 2008
Pediatric-onset multiple sclerosis in African-American black and European-origin white patientsAaron L Boster, Christina F Endress, Stephanie A Hreha, et al.
Neuromodulation : Journal of the International Neuromodulation Society|July 20, 2016
Best Practices for Intrathecal Baclofen Therapy: Screening TestAaron L Boster, Susan E Bennett, Gerald S Bilsky, et al.
Neuromodulation : Journal of the International Neuromodulation Society|July 20, 2016
Best Practices for Intrathecal Baclofen Therapy: Dosing and Long-Term ManagementAaron L Boster, Roy L Adair, Judith L Gooch, et al.
JAMA Neurology|January 23, 2013
Lessons learned from fatal progressive multifocal leukoencephalopathy in a patient with multiple sclerosis treated with natalizumabAaron L Boster, Jacqueline A Nicholas, Ilir Topalli, et al.
Stem Cells Translational Medicine|January 17, 2015
Concise review: modeling multiple sclerosis with stem cell biological platforms: toward functional validation of cellular and molecular phenotypes in inflammation-induced neurodegenerationJoshua C Orack, Michela Deleidi, David Pitt, et al.
Therapeutic Advances in Neurological Disorders|May 26, 2021
Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trialAlasdair J Coles, Douglas L Arnold, Ann D Bass, et al.
Pageof 2